Back to news

Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update

Globe Newswire•16/11/2026•18:31 ET
1

Key Highlights

  • ➤Revenue $6.4 million, up 24% quarter over quarter
  • ➤Operating loss $3.9 million, improves 18% year over year
  • ➤Operating expenses $7.2 million, down 17% year over year
  • ➤Vivos exchanged approximately $6.1 million debt for equity during 2026
  • ➤Vivos regained Nasdaq stockholders’ equity compliance after SOD Sciences transaction

Expert Statements

Kirk Huntsman, Chairman and Chief Executive Officer of Vivos Therapeutics

“During the third quarter of 2026, we took decisive steps to reduce costs and strengthen our balance sheet. Our operating loss improved 18% compared to the prior-year quarter, general and administrative and sales and marketing expenses together declined by $1.6 million, and we have now eliminated an estimated $5 million or more in annual operating costs, with further efficiencies underway. We also exchanged approximately $6.1 million of senior secured debt for equity during 2026 and, following the closing of our SOD Sciences transaction in October, regained compliance with Nasdaq’s stockholders’ equity requirement.”

Kirk Huntsman, Chairman and Chief Executive Officer of Vivos Therapeutics

“We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.”

Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance with Nasdaq stockholders’ equity requirement

LITTLETON, Colo., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, today reported financial results and operating highlights for the three and nine months ended September 30, 2026.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in